Clinical Trial Update: GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

View source ↗

Summary

Clinical trial update for GIOTRIF in first-line therapy of advanced non-small cell lung cancer with EGFR mutations; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Giotrif (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED | Results posted: 2020-01-09